The European Medicines Agency will review GSK's request to approve its asthma drug Nucala as an additional treatment for ...

The European Medicines Agency (EMA) has agreed to review GSK’s application of expanding Nucala’s (mepolizumab) use as add-on ...

GSK plc GSK announced that the European Medicines Agency (“EMA”) has accepted for review a regulatory filing, seeking ...

GSK (GSK) plc announced that the European Medicines Agency has accepted for review its application to expand the use of Nucala, a monoclonal ...

GSK shares are trading cheaply and offering potential passive income. So is this FTSE 100 stock a no-brainer buy for my ...

Recent health news highlights a 10% rise in child TB infections in Europe, detected mammal bird flu cases, and economic ...

If approved, the monoclonal antibody is expected to become the initial monthly-dosed biologic for COPD. GSK’s application is underpinned by the positive outcomes from the Phase III MATINEE trial ...

EMA accepts for review GSK’s application to expand use of Nucala for COPD treatment: London, UK Wednesday, March 26, 2025, 11:00 Hrs [IST] GSK plc announced that the European Me ...

GSK said on Monday that the European Medicines Agency has accepted its application to expand the use of ‘Nucala’, or ...

Currently, Nucala is not approved for treating COPD anywhere in the world. Year to date, shares of GSK have gained 16.1% compared with the industry’s rise of 5.7%. The regulatory application ...